Business Description
Affimed NV
NAICS : 325414
SIC : 2836
ISIN : NL0015001ZQ0
Description
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.77 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.34 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Altman Z-Score | -9.29 | |||||
| Beneish M-Score | 4.44 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -47.3 | |||||
| 3-Year EBITDA Growth Rate | -8.5 | |||||
| 3-Year EPS without NRI Growth Rate | -13.2 | |||||
| 3-Year FCF Growth Rate | -42.2 | |||||
| 3-Year Book Growth Rate | -22.2 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.49 | |||||
| 9-Day RSI | 45.62 | |||||
| 14-Day RSI | 46.3 | |||||
| 6-1 Month Momentum % | 73.49 | |||||
| 12-1 Month Momentum % | -29.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.25 | |||||
| Quick Ratio | 3.23 | |||||
| Cash Ratio | 2.81 | |||||
| Days Sales Outstanding | 129.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.1 | |||||
| Shareholder Yield % | 0.06 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1348.92 | |||||
| Net Margin % | -1285.25 | |||||
| FCF Margin % | -1384.4 | |||||
| ROE % | -104.18 | |||||
| ROA % | -73.84 | |||||
| ROIC % | -618.41 | |||||
| ROC (Joel Greenblatt) % | -1341.23 | |||||
| ROCE % | -91.16 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.87 | |||||
| PB Ratio | 1.25 | |||||
| Price-to-Tangible-Book | 1.25 | |||||
| EV-to-EBIT | -0.2 | |||||
| EV-to-EBITDA | -0.21 | |||||
| EV-to-Revenue | 2.56 | |||||
| EV-to-Forward-Revenue | 19.28 | |||||
| EV-to-FCF | -0.18 | |||||
| Price-to-Net-Current-Asset-Value | 1.62 | |||||
| Price-to-Net-Cash | 2.16 | |||||
| Earnings Yield (Greenblatt) % | -500 | |||||
| FCF Yield % | -153.17 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers